Given that in pancreatic (and other) cancers, multiple mechanisms often work in synchrony to lead to chemoresistance, considering more tailored treatment combinations that involve inhibition of Src, other molecular targets, plus tumour‐debulking cytotoxic agents may present a more effective approach. The gene discussed is SRC; the disease is cancer.